Page 1

Hypera pharma Hypera Pharma reports Net Revenue of R $ 4.089 billion in 2020 , up 24.1 % vs. 2019 , with 19.4 % growth in EBITDA from Continuing Operations São Paulo , February 26 , 2021 - Hypera S.A. ( " Hypera Pharma " or " Company " ; B3 : HYPE3 ; Bloomberg : HYPE3 BZ ; ISIN : BRHYPEACNORO ; Reuters : HYPE3.SA ; ADR : HYPMY ) announces its financial results for 2020. Financial data disclosed here are taken from the consolidated financial statements of Hypera S.A. , prepared in accordance with the Brazilian Accounting Pronouncement Committee ( CPC ) and International Financial Reporting Standards ( IFRS ) issued by the International Accounting Standards Board ( IASB ) . 4Q20 Highlights • Sell - out growth of 14.6 % * in 4Q20 , the highest ever recorded in a quarter by the Company , according to IQVIA • Net revenue of R $ 1,134.8 million in the quarter , or 22.2 % higher than 4Q19 2020 Highlights • Net revenue of R $ 4,088.9 million in 2020 , or 24.1 % higher than 2019 • EBITDA from Continuing Operations growth of 19.4 % in 2020 • Net Income from Continuing Operations of R $ 1,321.6 million in the year , with an increase of 11.2 % over 2019 • Higher than ever recorded Cash Flow from Continuing Operations in 2020 , up 43.6 % versus the previous year Interest on Equity of R $ 742.0 million ( R $ 1.17 per share ) in the year , or 10 % higher than 2019 • Table 1 ( R $ million ) 4Q19 % NR 4Q20 % NR A % 2019 % NR 2020 % NR A % Gross Revenue , net of Returns and Unconditional Discounts 1,093.7 Net Revenue 928.6 117.8 % 1,318.4 100.0 % 1,134.8 116.2 % 20.5 % 3,802.4 100.0 % 22.2 % 115.4 % 4,666.5 114.1 % 3,294.7 100.0 % 4,088.9 22.7 % 100.0 % 24.1 % Gross Profit 553.4 59.6 % 699.7 61.7 % 26.4 % 2,085.7 63.3 % 2,629.3 64.3 % 26.1 % SG & A ( ex - Marketing and R & D ) ( 162.7 ) -17.5 % ( 180.0 ) -15.9 % 10.6 % ( 638.8 ) -19.4 % ( 625.3 ) -15.3 % -2.1 % Research & Development Marketing ( 36.3 ) -3.9 % ( 34.7 ) ( 204.0 ) -22.0 % ( 214.7 ) -3.1 % -4.4 % ( 128.7 ) -3.9 % ( 151.7 ) -3.7 % 17.8 % -18.9 % 5.2 % ( 843.3 ) -25.6 % ( 787.0 ) -19.2 % -6.7 % EBITDA from Continuing Operations 224.2 24.1 % 349.0 30.8 % 55.7 % 1,206.0 36.6 % 1,440.4 35.2 % 19.4 % Net Income from Continuing Operations 246.7 26.6 % 324.9 28.6 % 31.7 % 1,189.0 Net Income 238.8 25.7 % 314.9 27.7 % 31.9 % 1,164.0 36.1 % 1,321.6 32.3 % 35.3 % 1,295.1 11.2 % 31.7 % 11.3 % Cash Flow from Operations 137.5 14.8 % 195.2 17.2 % 42.0 % 823.9 25.0 % 1,183.1 28.9 % 43.6 % 1 Earnings Conference Call - PORTUGUESE : 03/01/2021 , 11am ( Brasília ) / 9am ( New York ) Webcast : click here / Phone : +55 11 3181-8565 ( Code - Hypera ) Replay : +55 ( 11 ) 3193-1012 or +55 ( 11 ) 2820-4012 ( Code - 5476238 # ) or website ri.hypera.com.br Earnings Conference Call - ENGLISH ( Simultaneous translation ) : 03/01/2021 , 11am ( Brasília ) / 9am ( New York ) Webcast : click here / Phone : US Toll Free ++ 1 412 717-9627 | International +1 412 717-9627 ( Code - Hypera ) Replay : +55 ( 11 ) 3193-1012 ( Code - 8440138 # ) or website ri.hypera.com.br * Sell - out PPP 4Q20 ( Pharmacy Purchase Price ) , as informed by IQVIA , considers the drug stores and big retailers average purchase price . IR contacts +55 ( 11 ) 3627-4206 +55 ( 11 ) 3627-4097 ri@hypera.com.br